Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Prostate Cancer: early-phase trial registry
275 of 749 indexed Prostate Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #4 of 28,707 conditions by registered trial count.
749 US clinical trials · 275 currently recruiting · #4 of 28,707 conditions by registered trial count
Prostate Cancer: 749 US clinical trials tracked, 275 recruiting.
Prostate Cancer is the subject of 749 registered US clinical trials on ClinicalTrials.gov, 275 of them currently open to new participants. 75 are in Phase 3-4 (later-stage) and 344 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 53 of these trials.
Enrollment posture brief
Registry condition prostate-cancer
OPEN 275 | RECR 37% | LATE 75 | EARLY 344 | RANK #4 | SPON 53
Volume-matched condition peers
Nearest open-share peer: Chronic Disease (37% recruiting · 49 trials)
Prostate Cancer lists 275 open slots (37% of 749 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Prostate Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Prostate Cancer recruits in line with its size-band peers.
275 of 749 indexed trials (36.7%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Prostate Cancer trials is spread across many organizations.
Memorial Sloan Kettering Cancer Center accounts for 53 of 749 trials (7.1%). 283 distinct sponsors appear on at least one study for this condition label.
-
Typical Prostate Cancer enrolment sits around 82 participants.
Median target enrolment is 82 among the 736 trials that report a genuine target (sentinel values excluded). 389 of those (52.9%) plan for fewer than 100 participants.
-
Prostate Cancer research is mostly interventional.
628 interventional and 121 observational studies make up this index (83.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
749 total, page 14 of 15
Safety and Effectiveness Study of Docetaxel and ZD1839 Followed by Removal of the Prostate to Treat Prostate Cancer
Benaroya Research Institute
NCT00242918
Phase I Trial of Fixed Dose STI571 (Imatinib Mesylate) With Escalating Doses of Docetaxel in Patients With Metastatic Androgen-Independent Prostate Cancer
M.D. Anderson Cancer Center
NCT00038194
Postoperative Radiation Therapy, Hormonal Therapy and Concurrent Docetaxel for High Risk Pathologic Prostate Cancer
University of Kansas Medical Center
NCT00669162
Safety Study & Effectiveness of Docetaxel With RAD001 and Bevacizumab in Men With Advanced Prostate Cancer
University of Southern California
NCT00574769
Behavioral Exercise TRaining for Men Undergoing Androgen Depr Therapy for Prostate Ca
Virginia Commonwealth University
NCT06250751
Bone Mineral Density and Cancer Recurrence in Patients With Early Stage Prostate Cancer
University of Medicine and Dentistry of New Jersey
NCT00176579
Radium 223 in Castrate Resistant Prostate Cancer Bone Metastases
M.D. Anderson Cancer Center
NCT02135484
XL-184+Abiraterone in Post-Chemo CRPC
Dana-Farber Cancer Institute
NCT01574937
Ablation of Prostate Tissue Utilizing Sterile Water Vapor in Patients With Intermediate Risk Localized Prostate Cancer
Francis Medical
NCT04087980
Radiation Therapy Plus Amifostine in Treating Patients With Primary Prostate Cancer
University of Arizona
NCT00003307
Genetic Investigation of Solid Tumors Cohort
Scripps Translational Science Institute
NCT01005225
Enzalutamide and Metformin Hydrochloride in Treating Patients With Hormone-Resistant Prostate Cancer
University of California, Davis
NCT02339168
Growth Factor Levels in the Blood of Patients Undergoing Radiation Therapy for Epithelial Cancer
Vanderbilt-Ingram Cancer Center
NCT00897793
Study Using CP-461 to Treat Advanced Prostate Cancer
Astellas Pharma
NCT00036075
Satraplatin and Prednisone to Treat Prostate Cancer
National Cancer Institute (NCI)
NCT00634647
Gadoxetate Enhanced Imaging Study to Detect Prostate Cancer
National Cancer Institute (NCI)
NCT01867424
A Phase 1 Study of IS-002 Injection in Patients Undergoing Robotic Prostatectomy
Intuitive Surgical
NCT04574401
Pilot Study to Assess the Safety and Efficacy of BioProtect Balloon in Prostate Cancer Subjects
BioProtect
NCT00918229
Test-Retest Reproducibility of 18F-DCFPyL PET/CT in the Evaluation of Patients With Metastatic Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT03793543
Internal Radiation Therapy in Treating Patients With Prostate Cancer
Memorial Sloan Kettering Cancer Center
NCT00573833
Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies
Novita Pharmaceuticals
NCT03199586
Study of the Efficacy, Safety, and Pharmacokinetics of SM88 in Patients With Prostate Cancer
Tyme
NCT02796898
Study of Acai Juice in Asymptomatic or Minimally Symptomatic Prostate Cancer Patients With Rising PSA
University of Colorado, Denver
NCT01521949
MRI-Targeted Focal Ablation of the Prostate in Men With Prostate Cancer
NYU Langone Health
NCT02303054
Med Diet Prevention Metabolic Syndrome Men Undergoing Androgen Deprivation Therapy Prostate Cancer
Brown University
NCT01083771
Vaccine Therapy Plus QS21 in Treating Patients With Progressive Prostate Cancer
Memorial Sloan Kettering Cancer Center
NCT00003819
Magnetic Resonance Imaging to Locate and Characterize Prostate Cancer
National Cancer Institute (NCI)
NCT00082147
Cancer Localization in the Prostate With F-18 Fluorocholine Positron Emission Tomography
Queen's Medical Center
NCT01310192
Early Assessment of Treatment Response Using Functional Diffusion Mapping
University of Michigan Rogel Cancer Center
NCT02064283
PSMA Imaging of Localized Prostate Cancer
Weill Medical College of Cornell University
NCT03675451
A Phase 1 Trial for Evaluation of the Safety, Pharmacokinetics, and [18F] Radiation Dosimetry of CTT1057
Cancer Targeted Technology
NCT02916537
Lycopene in Healthy Male Participants
National Cancer Institute (NCI)
NCT00450957
Prospective Evaluation of a Commercially Available Hydrogel Spacer
BioProtect
NCT05323747
Prophylactic Urethral Stenting With Memokath After Prostate Implantation for Prostate Adenocarcinoma
The Cleveland Clinic
NCT00252941
Dendreon Lymph Node Biopsy in Metastatic Castrate-Resistant Prostate Cancer
Duke University
NCT02036918
A Phase 2 Study to Investigate the Clinical Activity of IPI-504 in Patients With Hormone-resistant Prostate Cancer
Infinity Pharmaceuticals
NCT00564928
Comparison of PET With [89Zr]-Df-IAb2M and [111In]-Capromab Pendetide in the Detection of Prostate Cancer Pre-Prostatectomy
ImaginAb
NCT02349022
Tetrathiomolybdate in Hormone Refractory Prostate Cancer
University of Michigan Rogel Cancer Center
NCT00150995
A Pilot Trial Using BR55 Ultrasound Contrast Agent in the Assessment of Prostate Cancer
Bracco Diagnostics
NCT02142608
A Study Comparing Oral Picoplatin With Intravenous Picoplatin in Subjects With Solid Tumors
Poniard Pharmaceuticals
NCT00465725
Selenium in Treating Patients Who Are Undergoing Brachytherapy for Stage I or Stage II Prostate Cancer
Roswell Park Cancer Institute
NCT00217516
Study to Compare the Effects of Repeated Doses of an Investigational New Drug and a Placebo on Appetite in Advanced Cancer and Anorexia
Pfizer
NCT04803305
Effect of Androgen Deprivation Therapy on Cardiovascular Function in Prostate Cancer
Kansas State University
NCT03275181
Neoadjuvant Stereotactic Body Radiotherapy Prior to Radical Prostatectomy for High Risk Prostate Cancer
University of Michigan Rogel Cancer Center
NCT02946008
Digoxin for Recurrent Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
NCT01162135
Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors
Masonic Cancer Center, University of Minnesota
NCT00703638
Incorporating MR Imaging Into Prostate Radiotherapy Treatment Planning
Dana-Farber Cancer Institute
NCT02470910
Vaccination of Prostate Cancer Patients With MUC-2-KLH Conjugate Plus the Immunological Adjuvant QS21
Memorial Sloan Kettering Cancer Center
NCT00698711
Evaluation Of Transperineal Ultrasound For Image Guidance In The Treatment Of Prostate Cancer in Men Following Prostatectomy
University of Vermont Medical Center
NCT02110667
Using Fiducial Markers to Aid in Prostate Cancer Radiation Treatment
National Cancer Institute (NCI)
NCT00061347
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 156 |
| Phase 2 | 188 |
| Phase 3 | 62 |
| Phase 4 | 13 |
Top Sponsors
Named interventions
Most-linked intervention names on Prostate Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Prostate Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Prostate Cancer page
749 registered trials, 275 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 275 Prostate Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Prostate Cancer trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Prostate Cancer condition card totals 749 registered trials; most-linked intervention Enzalutamide; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.